Susquehanna International Group
ASBP

Susquehanna International Group’s Aspire Biopharma ASBP Stock Holding History

Susquehanna International Group’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13
Closed -$9.34K – 13993
2025
Q1 		$9.34K Buy
+13
New +$89.9K ﹤0.01% 12219

Other funds holding ASBP

PA
Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return
CA
Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return
OAS
Optivise Advisory Services Franklin, Tennessee $197M AUM 26.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VAS
VR Advisory Services Camana Bay, Grand Cayman, Cayman Islands $845M AUM 22.79% 1-Year Est. Return
TSW
Three Seasons Wealth Salt Lake City, Utah $262M AUM 45.03% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
VWM
Valley Wealth Managers Paramus, New Jersey $1.55B AUM 28.47% 1-Year Est. Return
PTP
Platform Technology Partners New York $611M AUM 25.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group's ASBP Position: Q2 2025 in Review

Susquehanna International Group sold out of Aspire Biopharma (ASBP) in Q2 2025, closing a stake of 13 shares — an estimated $9.34K sold.

Susquehanna International Group first reported a position in ASBP in Q1 2025 and held it in 1 quarter. The position peaked at $9.34K in Q1 2025. 14 funds tracked by Wall St. Rank hold ASBP as of Q2 2025.

  • Susquehanna International Group reported no remaining Aspire Biopharma position as of Q2 2025 after selling out during the quarter.
  • Susquehanna International Group sold 13 Aspire Biopharma shares in Q2 2025, an estimated $9.34K.
  • Susquehanna International Group first reported a position in Aspire Biopharma in Q1 2025 and held it in 1 quarter.
  • Susquehanna International Group's Aspire Biopharma position peaked at $9.34K in Q1 2025.
  • 14 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2025.

Based on Susquehanna International Group's 13F filing for Q2 2025, filed 14 Aug 2025.